Evotec stock faces earnings estimate cut as ADR trades below $2
Published on 08/18/2026 at 17:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Evotec SE (ISIN DE0005664809) stock is contending with lower profit expectations for 2026, as its Nasdaq ADR trades at $1.96 as of August 17, 2026, highlighting a difficult year for the German biotech group.
ADR price and recent market performance
The Evotec ADR on Nasdaq, trading under the symbol EVO, closed at $1.96 on August 17, 2026, with the latest data showing the price unchanged at that level at 4:00 p.m. ET. Recent market data put Evotec's market capitalization at $697.29 million based on this closing price.
According to the same overview, Evo shares were at $3.08 at the start of 2026, meaning the ADR has fallen by 36.4 percent year-to-date to the current $1.96 level. The 52-week range for the ADR is reported between $1.90 and $4.27, so the latest quote sits close to the bottom of the recent trading corridor. For investors, this places the stock in a low part of its one-year range while consensus still implies upside from current levels.
Analyst forecasts and 2026 earnings expectations
Fresh earnings research points to deeper losses for Evotec in the near term. A new analyst note dated August 14, 2026 lowered the forecast for Evotec's Q3 2026 earnings per share to a loss of $0.14, compared with a previous estimate of a $0.04 loss.
The same update sets the projected Q4 2026 EPS at a $0.14 loss as well, and revises the full-year 2026 earnings forecast to a loss of $0.83 per share. In the broader consensus snapshot compiled on August 18, 2026, Evotec's current full-year EPS estimate stands at a loss of $0.98 per share. This indicates that the new bank model is modestly less pessimistic than the average, but both point to continued negative earnings for the year.
Despite these loss projections, the new analyst report maintains a buy rating with a $4.00 price target for the ADR. At the latest $1.96 price, this target implies measured upside potential of a little more than double, although the wider consensus price target quoted in the same data set is $3.00, which equals a 53.1 percent gain from the current level. The bank-specific $4.00 view therefore sits above the broader $3.00 average, underscoring differing opinions on Evotec's recovery path.
The consensus rating itself is summarized as Hold, based on a mix of buy, hold, and sell recommendations. With no strong buy ratings and one sell rating referenced in the same market overview, the sentiment around Evotec remains cautious, reflecting the expected losses and the drawn-out recovery timeline embedded in models that extend through FY2029 and FY2030.
Recent trading in Frankfurt and 52-week range
Evotec also continues to trade in Frankfurt under the symbol EVT. A same-day quote snapshot for the German listing on August 18, 2026 shows the local share closing at EUR 3.548, down 7.84 percent on the day with a decline of EUR 0.302 from the previous close of EUR 3.850. The Frankfurt price overview lists the day's trading range between EUR 3.506 and EUR 3.880, with a 52-week corridor from EUR 3.176 to EUR 7.300.
Comparing the latest EUR 3.548 close in Frankfurt to the 52-week high of EUR 7.300, Evotec's German shares are trading more than 50 percent below their one-year peak. Against the 52-week low of EUR 3.176, the current level is only modestly higher, signaling that sentiment in the home market is also subdued. The international ADR picture and the domestic share performance therefore align, painting a picture of a stock that has retraced significantly from earlier highs.
Fundamentals and growth outlook for 2026
While detailed reported figures for the latest quarter are not fully spelled out in the same set of sources, the earnings estimates for Q3 and Q4 2026 and the full-year forecasts give a structured view of expectations for Evotec's profitability path. The shift from a projected Q3 2026 loss of $0.04 per share to a $0.14 loss indicates that analysts expect either lower revenue, higher costs, or a combination of both over the coming months.
The full-year 2026 loss forecast of $0.83 per share in the revised model compares against the broader consensus of a $0.98 loss, suggesting that some forecasters see room for incremental operational improvement versus the average view. Longer-term projections for FY2029 and FY2030 in the same note move into positive territory, with EPS estimates of $0.21 and $0.28, respectively, signaling a gradual path back to profitability if Evotec executes on its pipeline and contract research opportunities.
In addition, the consensus price target of $3.00 on the ADR indicates that analysts collectively expect significant value creation from the current $1.96 price over time, assuming the company can translate its drug discovery collaborations and biologics manufacturing capabilities into growing revenue. The fact that the ADR has dropped from $3.08 at the start of 2026 to $1.96 by mid-August, a decline of 36.4 percent, highlights the gap between expectations and realized performance so far.
Partnerships and AI-enabled discovery efforts
Evotec's business model centers on partnering with pharmaceutical and biotech companies on drug discovery programs, using both small-molecule and biologics platforms. A recent collaboration announced in early August 2026 describes Evotec teaming up with Odyssey Therapeutics on AI-enabled research and development to accelerate the identification of promising targets and candidates in complex disease areas. A news overview for the ADR lists this AI-enabled collaboration as a notable recent development on August 7, 2026.
With this type of AI-based R&D partnership, Evotec aims to leverage advanced computing and machine learning to reduce the time and cost associated with early-stage discovery. The long-dated earnings projections that turn positive in FY2029 and FY2030 implicitly rely on such collaborations generating milestones, research fees, and potential downstream royalty streams. For investors, the collaboration pipeline is therefore central to the thesis that current losses can eventually give way to sustained profitability.
Evotec also operates biologics manufacturing capabilities, including its Just-Evotec Biologics platform, which focuses on efficient, continuous processing for antibody and protein production. Historical transaction news referenced in a July 30, 2025 headline shows that Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France were subject to an acquisition agreement, underscoring the strategic value of these assets within the broader biopharmaceutical ecosystem. While that deal predates the current 2026 window, it illustrates how Evotec's platforms can attract external interest and potentially reshape its revenue mix.
Representative platform: Just-Evotec Biologics
Evotec's Just-Evotec Biologics platform is a key representative product and service offering in its portfolio. The platform is designed to provide integrated solutions for biologics discovery and manufacturing, using modular, highly automated processes to deliver antibodies and other protein therapeutics at scale. This offering allows partners to move from early discovery through clinical manufacturing within a single technology and service framework, aiming to reduce both timelines and costs for complex biologics projects.
By combining process-development expertise with advanced continuous manufacturing infrastructure, Just-Evotec Biologics can support both large pharmaceutical clients and emerging biotech firms seeking flexible capacity. For Evotec, this platform is not just a technology asset but also a revenue driver, as projects can generate discovery fees, development payments, and long-term supply agreements. In the context of the longer-term earnings estimates that turn positive in FY2029 and FY2030, sustained utilization of Just-Evotec Biologics and similar platforms is likely to be a core factor in achieving the forecasted profitability.
Evotec stock valuation and investor takeaway
At the latest Nasdaq ADR price of $1.96 as of August 17, 2026, Evotec stock trades well below both the $3.00 consensus price target and the $4.00 target cited in the recent bank research note. With the ADR having declined 36.4 percent from its January 1, 2026 level of $3.08, current valuations reflect market skepticism around near-term earnings and execution risks, even as models still point to room for upside over a multi-year horizon.
For investors evaluating Evotec, the key numbers currently in view are the projected Q3 and Q4 2026 EPS losses of $0.14, the full-year 2026 loss forecasts ranging from $0.83 to $0.98 per share, the $1.96 ADR price close on August 17, 2026, and the EUR 3.548 Frankfurt price with a 52-week range between EUR 3.176 and EUR 7.300. Taken together, these figures show a company in an investment phase with negative earnings, yet one that still commands a substantial market capitalization just below $700 million and maintains analyst expectations for eventual profit recovery.
Go deeper
Read more background on Evotec stock, its dual listing structure and ADR history in the context of German technology companies accessing U.S. markets in the early 2020s. A legal and capital markets analysis published on August 18, 2026 highlights how Evotec expanded from its original Frankfurt listing to a Nasdaq Level III ADR program to reach a broader investor base.
Investor Relations
Further details on Evotec's strategy, pipeline, and financial reporting can be found on the company investor relations pages and in its most recent quarterly and annual reports, which outline current projects, collaboration milestones, and guidance for the year.
Fact box
Company: Evotec SE
ISIN: DE0005664809
Ticker: EVO, EVT
Exchange: Nasdaq (ADR), Xetra/Frankfurt
Price (as of August 17, 2026, 4:00 p.m. ET): $1.96 USD
Market cap: $697.29 million (as of August 17, 2026)
Sector / Industry: Biotechnology, drug discovery and development services
Index membership: MDAX (historical reference), local German index composition subject to regular review
